Concepedia

Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice

Bo-Wen Lin, Nobutaka Koibuchi, Yu Hasegawa, Daisuke Sueta, Kensuke Toyama, Ken Uekawa, Mingjie Ma, Takashi Nakagawa, Hiroaki Kusaka, Shokei Kim‐Mitsuyama

Cardiovascular Diabetology · 2014 · 403 citations · 34 references

DOIFull text

Open access

References

34

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

Irene Stratton · BMJ · 2000 · 8.9K citations · Full text

Effects of Intensive Glucose Lowering in Type 2 Diabetes

New England Journal of Medicine · 2008 · 7.8K citations · Full text

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

Rury R. Holman, Sanjoy K. Paul, M. Angelyn Bethel et al. · New England Journal of Medicine · 2008 · 7.6K citations · Full text

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

Benjamin M. Scirica, Deepak L. Bhatt, Eugene Braunwald et al. · New England Journal of Medicine · 2013 · 3.4K citations · Full text

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

William B. White, Christopher P. Cannon, Simon Heller et al. · New England Journal of Medicine · 2013 · 2.5K citations · Full text